ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2938

Is Synovial Hypertrophy without Doppler Activity in Rheumatoid Arthritis Joints Sensitive to Change ? – Results of a Longitudinal Ultrasound Study

Lene Terslev1, Mikkel Østergaard1, Joseph Sexton2 and Hilde B Hammer2, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Rheumatoid arthritis (RA), treatment and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 8, 2017

Title: Imaging of Rheumatic Diseases II: Focus on Rheumatoid Arthritis and Systemic Sclerosis

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Ultrasound (US) is used to assess diseases activity in rheumatoid arthritis (RA). Gray scale (GS) US shows the synovial hypertrophy (SH) and Doppler the amount of hyperemia which is believed to reflect disease activity. Some joints with SH may have no Doppler activity despite the use of high-end US equipment and these joints are generally believed to be inactive without potential to change. The aim is to investigate if joints with SH but no Doppler activity is sensitive to change during treatment with biological DMARD (bDMARD) in RA patients

Methods:

RA patients initiating or changing bDMARD treatment were included. US examination was performed at baseline, 3 and 6 months using Siemens Antares US equipment with Doppler settings for slow flow. 36 joints were evaluated at each visit. SH and Doppler activity was graded from 0-3 according to the US atlas by Hammer et al. The GS score for SH in joints without Doppler activity was registered for the individual joints using GS SH>1 as threshold. The changes were compared to changes in SH in joints with Doppler activity.

Results:

157 patients (83.2% women, 81.3% seropositive for anti-CCP and 75.8% for rheumatoid factor) were included, with a mean (SD) age of 51.5 (13.3) years and mean disease duration of 9.9 (8.1) years. At baseline, 52.2% used prednisolone (mean (SD) 7.7 (4.6) mg, range 2.5-25mg). The patients had a mean (SD) baseline DAS28 of 4.5 (1.5). At baseline 27% of the joints had SH without Doppler activity and 28% of the joints had SH with Doppler activity. Joints without Doppler had overall lower grades of SH (mean 0.72) than joints with Doppler (mean 1.21).

Of the joints that had SH without Doppler at baseline, 54% had a decrease in SH at 3 months, and 56% at 6 months. For joints with SH with Doppler at baseline, 52% had a decrease in SH at 3 months, and 60% at 6 months. The overall proportion of joints improving in SH was similar in joint with and without Doppler activity but when adjusting for the baseline score of SH, SH in joints without Doppler activity had a higher tendency towards decrease than those with Doppler activity (3 months: p <0.0001; 6 months < 0.0005).

Conclusion:

SH in joints without Doppler activity improves during bDMARD, i.e is sensitive to change. Thus, SH without Doppler activity is not a sign of inactive disease. These findings document that both Doppler and SH should be evaluated when assessing disease activity by US.


Disclosure: L. Terslev, None; M. Østergaard, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth, 5; J. Sexton, None; H. B. Hammer, AbbVie Norway, 2,Abbvie, 8,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 8,Roche Pharmaceuticals, 8.

To cite this abstract in AMA style:

Terslev L, Østergaard M, Sexton J, Hammer HB. Is Synovial Hypertrophy without Doppler Activity in Rheumatoid Arthritis Joints Sensitive to Change ? – Results of a Longitudinal Ultrasound Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/is-synovial-hypertrophy-without-doppler-activity-in-rheumatoid-arthritis-joints-sensitive-to-change-results-of-a-longitudinal-ultrasound-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-synovial-hypertrophy-without-doppler-activity-in-rheumatoid-arthritis-joints-sensitive-to-change-results-of-a-longitudinal-ultrasound-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology